Latest News for PSYGF
TORONTO, ON / ACCESS Newswire / May 21, 2026 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company") is pleased to announce the voting results from its annual general and special meeting of shareholders held today (the "Meeting"). At the Meeting, shareholders approved all matters brought before the Meeting, including matters relating to the Company's previously announced proposed amalgamation transaction…
NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Psyence BioMed Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company focused on the development and supply of nature-derived psychedelic compounds for clinical research and therapeutic applications, today announced that members of its executive leadership team will travel to the United States in the coming weeks to meet with researchers,…
Dosing initiates clinical evaluation of NPX-5, a GMP-compliant, nature-derived psilocybin candidate across an expanded Australian site network Dosing initiates clinical evaluation of NPX-5, a GMP-compliant, nature-derived psilocybin candidate across an expanded Australian site network
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for PSYGF.
Senate Trading
No Senate trades found for PSYGF.
U.S. House Trading
No House trades found for PSYGF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.